Original source text
, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v. VGXI, Inc. and GeneOne Life Science, Inc., No. 2020-06554, in the Court of Common Pleas of Montgomery County, Pennsylvania. The Court awarded INOVIO $61,750,789 in compensatory damages and $18,665,312 in fees and costs. The Court also entered judgment against defendants on their counterclaims.
INOVIO filed the case on June 3, 2020, when defendants breached the parties' Supply Agreement by refusing to honor their technology transfer obligations to enable scalable manufacturing of DNA plasmids.
Defendants' financial condition will likely impair INOVIO's ability to collect some or all of the judgment. INOVIO intends to use every reasonable effort to recover the damages awarded by this judgment.
Cooley LLP and FBT Gibbons served as trial counsel for INOVIO.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to INOVIO's business, including statements regarding INOVIO's ability to collect on and realize the ultimate value from the judgment entered in INOVIO's favor against VGXI and GeneOne and the impact of defendants' financial condition on INOVIO's ability to enforce or collect any portion of the judgment. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including the risk that the judgment may be reduced, reversed, or otherwise modified on post-trial motions or appeal; the risk that defendants' financial condition will likely impair INOVIO's ability to collect some or all of the judgment, associated interest, fees and costs, notwithstanding INOVIO's intent to use every reasonable effort to recover the damages awarded; the time, expense, and uncertainty associated with collection and enforcement efforts; the adequacy of INOVIO's capital resources; the level of corporate expenditures; capital market conditions; and other factors set forth in INOVIO's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings INOVIO makes from time to time with the Securities and Exchange Commission. There can be no assurance that INOVIO will collect any or all of the judgment, that the judgment will not be reduced, reversed, or otherwise modified, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and INOVIO undertakes no obligation to update or revise these statements, except as may be required by law.
Contacts
Media: Josephine Galatioto, ICR Healthcare, [email protected]
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.
|
Original source text
Palantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
Shea described Inovio as a clinical-stage company developing DNA medicines for HPV-related diseases, cancer and infectious diseases. The company’s platform uses plasmid DNA delivered through its proprietary CELLECTRA device, which applies brief electrical pulses to help the DNA enter skin or muscle cells. Once inside cells, the plasmids are transcribed into mRNA and translated into proteins intended to produce sustained protein levels or generate immune responses.
Get Inovio Pharmaceuticals alerts:
Let the Good Times Roll: 2 Stocks Showing No Signs of SlowingAccording to Shea, the platform is particularly suited to producing antigen-specific T-cell responses, which the company sees as important in cancer and virally mediated diseases. In the United States, CELLECTRA is regulated as part of a combination product rather than through a separate approval process. The device already has CE marking in the European Union, she said.
RRP Program Targets Repeat Surgery Burden RRP is caused primarily by HPV types 6 and 11 and can lead to wart-like papilloma growths around the vocal cords, Shea said. The condition can make speaking, swallowing and breathing difficult, while in some cases disease can spread through the respiratory tract and become malignant.
3 AI Stocks in Correction Mode: Can They Rebound?Current care generally relies on surgical removal of papillomas, either through laser procedures or scalpels. However, surgery does not eliminate the underlying virus, Shea said, meaning papillomas can return and patients can face repeat procedures. Those procedures can also cause permanent scarring or damage to vocal cords and respiratory tissues.
Inovio’s Phase I/II study of INO-3107 enrolled 32 patients with confirmed HPV 6- or HPV 11-associated RRP who had undergone two to eight surgeries in the preceding year. Patients received four doses over nine weeks after a clinically required surgery.
In the first year after treatment, 72% of patients experienced a 50% to 100% reduction in surgeries compared with the prior year, according to Shea. That figure increased to 86% in the second year. Twenty-eight percent of patients required no surgeries in year one, rising to 50% in year two. Shea said the trial showed mainly grade 1 and grade 2 adverse events, with few systemic events. She also said patients have reported mild-to-moderate injection-site discomfort from the CELLECTRA administration process that generally resolves within five to 10 minutes.
FDA Review and Potential Confirmatory Trial INO-3107’s biologics license application was submitted under the accelerated approval pathway. Shea said the FDA’s file acceptance letter included a preliminary conclusion that the application might not be eligible for review under that pathway.
Because an RRP product had previously received full approval, Inovio must demonstrate continuing unmet need and meaningful therapeutic benefit over available treatment to support accelerated approval, Shea said. The company subsequently submitted an assessment aid containing its clinical safety and efficacy data along with additional FDA-requested analyses.
Inovio held an informal clinical meeting with the FDA in July. Shea said company representatives were joined by patient advocacy organizations and a physician treating RRP patients, who discussed the continued unmet need and potential clinical benefit of INO-3107. The FDA did not comment on the review pathway at that time because the review was at a late stage, she said.
The company has completed pre-licensure inspections, receiving one observation that it believes has been resolved. Shea said Inovio expected to enter labeling discussions in September, while noting that the company would also need to confirm the design of any accelerated-approval confirmatory trial with the FDA.
Inovio had previously proposed a placebo-controlled study of about 100 patients, randomized two-to-one between active treatment and placebo. Shea said the study could include year-one and year-two readouts to confirm clinical benefit, although the FDA could request additional patients or endpoints.
Commercial Preparation and Pipeline Plans Shea said Inovio has made key commercial preparations for a potential launch, including partnerships for specialty distribution, specialty pharmacy, patient support and third-party logistics. The company is also working with Syneos Health for contract sales and medical science liaison deployment.
RRP treatment is concentrated among an estimated 300 to 400 laryngologists at roughly 100 U.S. treatment centers, Shea said. Inovio estimates at least 14,000 potential RRP patients based on claims-database work, though Shea said the company believes the number could be higher.
Beyond INO-3107, Inovio’s clinical pipeline includes INO-3112 for HPV 16- and HPV 18-positive head and neck cancer, partnered with Coherus, and a glioblastoma program partnered with Akeso. The company also has earlier-stage protein-replacement work in hemophilia A, Fabry disease and hypophosphatasia.
At the end of the second quarter, Inovio had $36.7 million in cash. Shea said a subsequent offering generated $18.3 million in net proceeds, extending the company’s cash runway into the end of the first quarter of 2027 and through a potential INO-3107 launch if approved.
About Inovio Pharmaceuticals (NASDAQ:INO)Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Inovio Pharmaceuticals Right Now?Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
|
Original source text
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences Current cash, cash equivalents, and short-term investments anticipated to fund operations into late first quarter 2027, through a potential launch of INO-3107, if approved , /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent company developments.
"As the FDA's review of our BLA for INO-3107 continues to advance, we are pleased to have held the informal clinical meeting with the FDA, where we presented the totality of data supporting INO-3107's safety and efficacy and highly differentiated approach in treating RRP, and our rationale for accelerated approval eligibility," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We are confident in INO-3107's potential to become the preferred product among patients, healthcare providers and payers, if approved, and are committed to ensuring that all patients have access to therapeutic options that work for them in reducing the need for surgery to control their disease. We look forward to the final stages of the review process and further advancing our commercial preparations."
Operational Highlights
INO-3107 – Recurrent Respiratory Papillomatosis (RRP)
The FDA's review of the BLA for INO-3107 continues to advance under the Agency's accelerated approval program toward a PDUFA target action date of October 30, 2026. Regulatory progress includes completion of the late-cycle review meeting and all scheduled pre-licensure inspections. An informal clinical meeting was conducted, where INOVIO presented the totality of data supporting INO-3107's safety and efficacy and highly differentiated approach in treating RRP, along with the company's rationale for accelerated approval eligibility. During the informal meeting, the FDA did not discuss its preliminary comment in the file acceptance letter regarding accelerated approval eligibility. In addition, the FDA stated that feedback on the confirmatory trial design would be forthcoming. INOVIO continues to believe that INO-3107 fulfills the criteria for accelerated approval by meeting an unmet clinical need and providing a meaningful therapeutic benefit over existing treatments.
In anticipation of a potential approval in 2026, INOVIO is preparing its commercial launch activities. Recently, INOVIO engaged Syneos Health to recruit and deploy Medical Science Liaisons (MSLs), and Syneos Health is also serving as the company's contract sales organization to support commercialization in the U.S. INOVIO has also engaged or identified key commercial partners, including a third-party logistics provider, Agency of Record, specialty distributor, specialty pharmacy, and patient hub.
The FDA previously granted INO-3107 both Orphan Drug and Breakthrough Therapy designations.
VGX-3100 – Cervical Dysplasia (High-grade Squamous Intraepithelial Lesions)
In May 2026, INOVIO's partner for VGX-3100 in Greater China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100 as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from the study to support a future filing for regulatory approval of VGX-3100 in China. VGX-3100 is INOVIO's investigational DNA immunotherapy developed for diseases associated with high-risk human papillomavirus (HPV) types 16 and 18.
Next-Generation DNA Medicine Candidates
INOVIO presented promising data from our next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at the American Society of Gene and Cell Therapy Annual Meeting in May 2026 and the World Orphan Drug Congress in June 2026, highlighting positive preclinical data on Factor VIII production for Hemophilia A. INOVIO is continuing discussions with potential partners to accelerate development of this promising platform with a focus on developing additional DPROT indications in the rare disease space, including Fabry Disease and Hypophosphatasia (HPP).
General Corporate
INOVIO remains focused on financial discipline, directing resources to advance the INO-3107 program toward a potential 2026 approval and preparing for commercialization. The company strengthened its balance sheet with an underwritten public equity offering in July 2026. Net proceeds from the offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $18.3 million.
Second Quarter 2026 Financial Results
Research and Development (R&D) Expenses: R&D expenses for the three months ended June 30, 2026 decreased to $10.8 million from $14.5 million for the same period in 2025. The decrease was primarily the result of lower employee and consultant compensation, including stock-based compensation, lower engineering outside services related to our device development, and lower inventory expenses, among other variances. General and Administrative (G&A) Expenses: G&A expenses decreased to $7.8 million for the three months ended June 30, 2026 from $8.6 million for the same period in 2025. Total Operating Expenses: Total operating expenses decreased to $18.6 million for the three months ended June 30, 2026 from $23.1 million for the same period in 2025. Net Loss: INOVIO's net loss for the three months ended June 30, 2026 was $6.0 million, or $0.07 per basic and diluted share, compared to a net loss of $23.5 million, or $0.61 per basic and diluted share, for the three months ended June 30, 2025. The decrease in net loss was primarily driven by a $13.9 million non-cash gain on fair value adjustment related to our warrant liabilities for the three months ended June 30, 2026. As the fair value of the warrants fluctuates with our share price and other market inputs, this adjustment can result in significant variability in our reported net loss. Cash, Cash Equivalents and Short-term Investments: As of June 30, 2026, cash, cash equivalents and short-term investments were $36.7 million (excluding net proceeds from the July 2026 offering of approximately $18.3 million), compared to $58.5 million as of December 31, 2025. Cash Guidance
INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into late first quarter 2027, through a potential launch of INO-3107, if approved. This projection includes the net proceeds of approximately $18.3 million from the public offering in July 2026, as well as an operational net cash burn estimate of approximately $18 million for the third quarter of 2026. These cash runway projections do not include any further capital-raising activities that INOVIO may undertake.
Conference Call / Webcast Information
INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including the timing and success of preclinical studies and clinical trials; the ability to obtain and maintain regulatory approval of our product candidates; the FDA's continued review of our BLA for INO-3107 toward a PDUFA target action date of October 30, 2026; the outcome of our meeting with the FDA to discuss eligibility for the accelerated approval program, including feedback on our proposed confirmatory trial design; the potential benefits of INO-3107 and our other potential product candidates, including our belief that INO-3107 has a positively differentiated product profile and the potential to become the preferred product by patients and their physicians, if approved; the scope, progress and expansion of developing and commercializing our product candidates, including the anticipated commercial launch of INO-3107, if approved; our anticipated growth strategies; our ability to establish and maintain development partnerships; our estimated operational net cash burn of approximately $18 million for the third quarter of 2026; and the expected sufficiency of our cash resources through a potential launch of INO-3107, if approved, and into late first quarter 2027. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, [email protected]
Inovio Pharmaceuticals, Inc.
CONSOLIDATED BALANCE SHEETS
June 30,
2026
December 31,
2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$31,526,164
$44,273,319
Short-term investments
5,147,853
14,239,145
Prepaid expenses and other current assets, including from affiliated entity
3,239,232
2,610,882
Total current assets
39,913,249
61,123,346
Fixed assets, net
1,888,725
2,527,603
Investments in affiliated entity
—
2,103,688
Operating lease right-of-use assets
5,670,451
6,542,923
Other assets
1,917,069
2,012,475
Total assets
$49,389,494
$74,310,035
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses
$11,653,162
$11,053,618
Accounts payable and accrued expenses due to affiliated entity
—
74,473
Accrued clinical trial expenses
338,461
650,680
Common stock warrant liabilities
25,024,799
29,067,162
Operating lease liability
2,898,637
2,822,622
Total current liabilities
39,915,059
43,668,555
Operating lease liability, net of current portion
5,103,352
6,545,204
Total liabilities
45,018,411
50,213,759
Stockholders' equity:
Preferred stock
—
—
Common stock
82,342
68,997
Additional paid-in capital
1,845,429,136
1,839,830,405
Accumulated deficit
(1,840,860,419)
(1,815,165,163)
Accumulated other comprehensive loss
(279,976)
(637,963)
Total Inovio Pharmaceuticals, Inc. stockholders' equity
4,371,083
24,096,276
Total liabilities and stockholders' equity
$49,389,494
$74,310,035
Inovio Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenues:
Revenue from collaborative arrangement
$—
$—
$—
$65,343
Operating expenses:
Research and development
10,826,549
14,521,407
24,896,656
30,612,309
General and administrative
7,797,973
8,563,112
15,677,859
17,588,082
Total operating expenses
18,624,522
23,084,519
40,574,515
48,200,391
Loss from operations
(18,624,522)
(23,084,519)
(40,574,515)
(48,135,048)
Other income (expense):
Interest income
363,847
610,638
803,440
1,418,715
Change in fair value of common stock warrant liabilities
13,868,616
(1,878,010)
18,006,319
1,834,862
Gain (loss) on investment in affiliated entity
—
776,373
(2,103,688)
1,471,504
Net unrealized gain on available-for-sale equity securities
94,221
759,289
173,298
899,523
Other expense, net
(1,714,620)
(703,183)
(2,000,110)
(703,665)
Net loss
$(6,012,458)
$(23,519,412)
$(25,695,256)
$(43,214,109)
Net loss per share
Basic and diluted
$(0.07)
$(0.61)
$(0.34)
$(1.12)
Weighted average number of common shares used to compute
net loss per share
Basic and diluted
81,619,113
38,830,053
75,395,090
38,722,451
SOURCE INOVIO Pharmaceuticals, Inc.
|
Original source text
, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof), in an underwritten public offering. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to 15% of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Piper Sandler is acting as sole manager for the offering.
A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
Forward-Looking Statements
This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding INOVIO's anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and INOVIO's plans to grant the underwriter a 30-day option to purchase additional shares and/or warrants. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Contacts
Media: Jennie Willson (267) 429-8567 [email protected]
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 [email protected]
SOURCE Inovio Pharmaceuticals, Inc.
|
